DB:107

Stock Analysis Report

Executive Summary

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.

Risk Analysis

Earnings have declined by -10.87% per year over past 5 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (CA$718K)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Bioasis Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 107's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.9%

107

-1.0%

DE Biotechs

1.7%

DE Market


1 Year Return

-47.0%

107

6.2%

DE Biotechs

15.0%

DE Market

Return vs Industry: 107 underperformed the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: 107 underperformed the German Market which returned 15% over the past year.


Shareholder returns

107IndustryMarket
7 Day16.9%-1.0%1.7%
30 Day-1.2%-2.3%0.8%
90 Day30.3%7.8%3.7%
1 Year-47.0%-47.0%6.4%6.2%18.5%15.0%
3 Yearn/a49.0%47.3%17.1%6.9%
5 Yearn/a12.6%10.3%24.3%7.3%

Price Volatility Vs. Market

How volatile is Bioasis Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bioasis Technologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Bioasis Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bioasis Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 107’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Bioasis Technologies regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Bioasis Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioasis Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bioasis Technologies performed over the past 5 years?

-10.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 107 is currently unprofitable.

Growing Profit Margin: 107 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 107 is unprofitable, and losses have increased over the past 5 years at a rate of -10.9% per year.

Accelerating Growth: Unable to compare 107's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 107 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 107's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Bioasis Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: 107 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 107 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 107 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 107's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 107 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 107 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 107 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 107 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8.6% each year


Next Steps

Dividend

What is Bioasis Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 107's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 107's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 107's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 107's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 107's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Deborah Rathjen (61yo)

0.9yrs

Tenure

CA$105,352

Compensation

Dr. Deborah Ann Rathjen, B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE, Q.C. has been the President and Chief Executive Officer of Bioasis Technologies Inc. since March 11, 2019. Dr. Rathjen served as the Chief E ...


Leadership Team

NamePositionTenureCompensationOwnership
Deborah Rathjen
Executive Chairman0.9yrsCA$105.35k0.28% CA$34.2k
Christine Antalik
Chief Financial Officer1.1yrsCA$304.70kno data
Caroline Dircks
Chief Operating Officer0.6yrsCA$511.50k0.072% CA$8.8k
José Iglesias
Chairperson of the Medical Oncology Advisory Board & Consultant Chief Medical Officer0.2yrsno datano data
Graeme Dick
Director of Investor Relations0yrsno datano data
Kim Elton
Director of Marketing0yrsno datano data
Doug Williams
Executive VP & Chief Business Officer2.5yrsno datano data
Mei Tian
VP & Head of External Research0yrsno datano data

0.9yrs

Average Tenure

Experienced Management: 107's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Deborah Rathjen
Executive Chairman0.9yrsCA$105.35k0.28% CA$34.2k
José Iglesias
Chairperson of the Medical Oncology Advisory Board & Consultant Chief Medical Officer0.2yrsno datano data
David Wurzer
Lead Director1.2yrsCA$152.42k0.084% CA$10.3k
Jeffrey Cummings
Member of Scientific Advisory Board2.4yrsno datano data
John Wikswo
Member of Scientific Advisory Board2.4yrsno datano data
John Krystal
Chairman of Scientific Advisory Board2.4yrsno datano data
Mario Saltarelli
Independent Non-Executive Director0.8yrsno datano data
Jack Hoppin
Member of Scientific Advisory Board1.7yrsno datano data
Sue O'Connor
Member of Scientific Advisory board1.7yrsno datano data
John Curran
Independent Director1.6yrsCA$152.42k0.084% CA$10.2k

1.7yrs

Average Tenure

61yo

Average Age

Experienced Board: 107's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bioasis Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioasis Technologies Inc.
  • Ticker: 107
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$17.483m
  • Listing Market Cap: CA$12.167m
  • Shares outstanding: 63.57m
  • Website: https://www.bioasis.us

Location

  • Bioasis Technologies Inc.
  • 14 Water Street
  • Guilford
  • Connecticut
  • 6437
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BTITSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2008
BIOA.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2008
107DB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2008

Biography

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company’s lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company’s in-house development programs develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to search for a platform for BBB delivery of therapeutics; and BioAgilytix for the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, as well as with the WuXi Biologics (Hong Kong) Limited for the manufacture of xB3-001 to treat brain cancer. The company was founded in 2007 and is headquartered in Guilford, Connecticut. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/16 22:39
End of Day Share Price2020/02/14 00:00
Earnings2019/11/30
Annual Earnings2019/02/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.